Oppenheimer Asset Management’s Utah Medical Products UTMD Stock Holding History

Oppenheimer Asset Management’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,592	Closed	-$150K	–	1430
2020 Q1	$150K	Sell	1,592 -11	-0.7%	-$1.02K	﹤0.01%	1025
2019 Q4	$173K	Sell	1,603 -21	-1%	-$2.13K	﹤0.01%	1087
2019 Q3	$156K	Buy	1,624 +23	+1%	+$2.14K	﹤0.01%	1091
2019 Q2	$153K	Buy	1,601 +158	+11%	+$13.3K	﹤0.01%	1116
2019 Q1	$127K	Buy	1,443 +45	+3%	+$3.96K	﹤0.01%	1150
2018 Q4	$116K	Buy	+1,398	New	+$123K	﹤0.01%	1154
2017 Q4	–	Sell	-907	Closed	-$67K	–	1477
2017 Q3	$67K	Buy	907 +99	+12%	+$7.12K	﹤0.01%	1300
2017 Q2	$58K	Buy	808 +463	+134%	+$30.5K	﹤0.01%	1313
2017 Q1	$21K	Buy	+345	New	+$21.7K	﹤0.01%	1470

Other funds holding UTMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Oppenheimer Asset Management's UTMD Position: Q2 2020 in Review

Oppenheimer Asset Management sold out of Utah Medical Products (UTMD) in Q2 2020, closing a stake of 1,592 shares — an estimated $150K sold.

Oppenheimer Asset Management first reported a position in UTMD in Q1 2017 and held it in 9 quarters. The position peaked at $173K in Q4 2019. 93 funds tracked by Wall St. Rank hold UTMD as of Q2 2020.

Oppenheimer Asset Management reported no remaining Utah Medical Products position as of Q2 2020 after selling out during the quarter.
Oppenheimer Asset Management sold 1,592 Utah Medical Products shares in Q2 2020, an estimated $150K.
Oppenheimer Asset Management first reported a position in Utah Medical Products in Q1 2017 and held it in 9 quarters.
Oppenheimer Asset Management's Utah Medical Products position peaked at $173K in Q4 2019.
93 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2020.

Based on Oppenheimer Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.